| Category | Details |
| Definition | Cancers encompass a group of diseases characterized by abnormal cell growth with the potential to invade or spread to other parts of the body. Palliative care focuses on managing symptoms such as pain, nausea, and loss of appetite to improve quality of life. |
| Global Epidemiology | Approximately 19.3 million new cancer cases and 10 million deaths occurred worldwide in 2020. |
| About 70% of cancer deaths occur in low- and middle-income countries. | |
| Cancer-related symptoms, including pain and cachexia, are highly prevalent in advanced stages. | |
| Prevalence in Key Regions | United States: Approximately 1.9 million new cases and 608,570 deaths in 2021. |
| European Union: Around 3.7 million new cases annually; cancer is the second leading cause of death. For instance, in 2021, cancer accounted for about 21.6% of total deaths in the EU, with significant variations among member states. | |
| India: Estimated 1.3 million new cases in 2020, with significant unmet needs for palliative care. A considerable proportion of patients are diagnosed at advanced stages, with many cancers presenting as locally advanced or metastatic. For instance, about 57% of breast cancer patients and 60% of cervical cancer patients were diagnosed at advanced stages, which complicates treatment options and outcomes. | |
| China: Approximately 4.5 million new cases and 3 million deaths in 2020, with increasing demand for symptom management. The number of cancer-related deaths in China reached about 2,992,600, representing around 30.2% of global cancer deaths. This statistic underscores the severity of cancer as a leading cause of mortality in the country. | |
| Caribbean: An estimated 112,000 new cases and 79,000 deaths in 2020; limited access to advanced palliative care and symptom management. | |
| Medicinal Cannabis Approvals | United States (FDA): Dronabinol (synthetic THC) approved for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in AIDS patients. |
| Canada: Nabilone approved for chemotherapy-induced nausea and vomiting since 1981. | |
| European Union (EMA): Nabiximols (Sativex) approved for spasticity in multiple sclerosis; off-label use in palliative care in some countries. | |
| Australia (TGA): Medicinal cannabis products approved for symptom management in cancer since 2016. | |
| Israel: Cannabis-based treatments authorized for palliative care in advanced cancer since the early 1990s. | |
| Therapeutic Cannabinoids | CBD (Cannabidiol): Exhibits anti-inflammatory and anxiolytic properties; supports pain management and appetite improvement. |
| THC (Tetrahydrocannabinol): Effective for pain relief, appetite stimulation, and nausea control; psychoactive effects may limit use. | |
| CBN (Cannabinol): Mild sedative effects; emerging evidence for palliative symptom management. CBN is often referred to as a “sleepy cannabinoid” and is claimed to have sedative properties. Some studies suggest that CBN can increase total sleep time and enhance both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. For instance, one study indicated that CBN increased NREM sleep duration and had effects comparable to conventional sleep medications like zolpidem, although it operates with much lower potency than THC | |
| THCV (Tetrahydrocannabivarin): Potential appetite modulation and anti-inflammatory effects; limited clinical data. | |
| Mechanism of Action | CBD: Reduces pain and inflammation by modulating CB2 receptors; may inhibit cancer cell growth in preclinical models. |
| THC: Activates CB1 and CB2 receptors to relieve pain, reduce nausea, and stimulate appetite. | |
| CBN: Enhances sedative and anti-inflammatory effects through interaction with cannabinoid and non-cannabinoid receptors. | |
| Key Clinical Studies | Pagano et al., 2023: Preliminary evidence suggests CBN may enhance sleep and appetite in cancer patients. |
| Abrams et al., 2021: Cannabinoids improved quality of life and reduced opioid use in palliative cancer patients. | |
| Lichtman et al., 2022: CBD and THC combination reduced chemotherapy-induced nausea and vomiting in phase III trials. | |
| Dosage Guidelines | THC (Oral): 2.5–5 mg/day for appetite stimulation; titrate to ~10 mg/day for pain management. |
| CBD (Oral): Starting dose 20–40 mg/day; titrate to 50–100 mg/day based on response. | |
| Nabiximols (Sativex): Up to 12 sprays/day (2.7 mg THC and 2.5 mg CBD per spray). | |
| Administration Methods | Oral Capsules: Consistent dosing; preferred for chronic symptom management. |
| Sublingual Sprays: Rapid absorption; useful for acute symptom relief. | |
| Inhalation: Effective for rapid onset of pain and nausea relief; dosing variability limits use. | |
| Adverse Effects | THC: Psychoactive effects such as dizziness, euphoria, and cognitive impairment; potential for dependency. |
| CBD: Generally mild side effects: fatigue, diarrhea, and altered appetite. | |
| Nabiximols: Common side effects include dry mouth, dizziness, and fatigue. | |
| Research Gaps | Long-term safety studies of cannabinoids in cancer palliative care are needed. |
| More research required on the synergistic effects of cannabinoids with conventional cancer treatments. | |
| Opportunities in the Caribbean | High Prevalence: Estimated ~100,000 new cancer cases annually; significant unmet needs for palliative care. |
| Cannabis Clinics: Establishing cannabinoid-focused palliative care clinics could address local needs and attract international patients. | |
| Research Hub: Leveraging regional expertise to develop cannabinoid-based therapies for cancer symptoms. |
